ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Sympathetic Activity in Individuals With the Metabolic Syndrome: Benefits of Lifestyle Interventions

This study is currently recruiting participants.
Verified by Bayside Health, September 2005

Sponsored by: Bayside Health
Information provided by: Bayside Health
ClinicalTrials.gov Identifier: NCT00163943
  Purpose

An abdominal distribution of fat is associated with the greatest heart disease risk, because commonly, several risk factors of metabolic origin (high blood pressure, unfavourable cholesterol profile, elevated blood sugar, impaired insulin action) cluster in these individuals. When this occurs the condition is called the 'metabolic syndrome' (MetS). The cause of the MetS is yet to be fully elucidated. Increased activity of the nervous system resulting in enhanced release of the stress hormone 'norepinephrine', may be one mechanism by which adverse cardiovascular and metabolic sequelae of the MetS might be mediated. Dietary weight loss, and exercise are first-line treatments for the MetS and provide an opportunity to prevent or delay the development of type 2 diabetes and heart disease in this high risk group. However, there is a paucity of data regarding the effects of these lifestyle factors on the nervous system. Furthermore, it is also unknown whether active weight loss ('negative energy balance') or a stable lower weight (weight loss maintenance) is more important in modifying MetS components and nervous system activity. The aims of the proposed project are:

  1. To determine whether dietary weight loss in combination with aerobic exercise is more beneficial than dietary weight loss alone in reducing nervous system activity and improving metabolic and cardiovascular parameters in middle-aged men and women with abdominal obesity and the MetS.
  2. To determine whether weight loss maintenance four months after active weight loss is associated with a preservation of clinical benefits.
  3. To study biological determinants of successful weight loss and weight loss maintenance.

Condition Intervention
Metabolic Syndrome X
Behavioral: Dietary weight loss +/- aerobic exercise

MedlinePlus related topics:   Exercise and Physical Fitness    Metabolic Syndrome    Weight Control   

ChemIDplus related topics:   Insulin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment
Official Title:   Neural Mechanisms Predisposing to Cardiovascular Risk in Individuals With the Metabolic Syndrome: Benefits of Dietary Weight Loss, Weight Loss Maintenance and Aerobic Exercise

Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • Whole-body sympathetic activity
  • Muscle sympathetic activity

Secondary Outcome Measures:
  • Insulin sensitivity
  • Lipid profile
  • Adipocytokines
  • Blood pressure
  • Baroreflex function
  • Forearm and calf blood flow

Estimated Enrollment:   66
Study Start Date:   April 2005
Estimated Study Completion Date:   December 2007

Show detailed description  Show Detailed Description

  Eligibility
Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Sixty six (33 male and 33 postmenopausal female) weight-stable (body mass index 26 to 39 kg/m2), sedentary, non-smoking subjects, aged 45 to 65 years will be recruited on the basis of having > 3 indices of the MetS as defined by Adult Treatment Panel (ATP) III criteria:

    • waist circumference > 102 cm for men and > 88 cm for women;
    • fasting plasma glucose level > 6.1 mmol/L, but nondiabetic (< 7.1 mmol/L);
    • fasting plasma triglyceride level > 1.69 mmol/L;
    • plasma high-density lipoprotein (HDL) level < 1.04 mmol/L (males) and < 1.29 mmol/L (females);
    • supine resting blood pressure > 130/85 mmHg and < 165/105 mmHg, at least 4 weeks off blood pressure lowering medications.

Exclusion Criteria:

Exclusion criteria will comprise:

  • A history of diabetes, secondary hypertension, sleep apnoea, cardiovascular, cerebrovascular, renal, liver, or thyroid disease
  • Inability to cease medications which may affect measured parameters
  • Inability or contraindication to exercise
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163943

Contacts
Contact: Nora E Straznicky, BPharm, PhD, MPH     61 3 8532 1371     Nora.Straznicky@baker.edu.au    
Contact: Elisabeth A Lambert, Bsc, MSc, PhD     61 8532 1345     Elisabeth.Lambert@baker.edu.au    

Locations
Australia, Victoria
Baker Heart Research Institute     Recruiting
      Melbourne, Victoria, Australia, 8008
      Contact: Nora E Straznicky, BPharm, PhD, MPH     61 3 8532 1371     Nora.Straznicky@baker.edu.au    
      Principal Investigator: Nora E Straznicky, BPharm, PhD, MPH            

Sponsors and Collaborators
Bayside Health

Investigators
Principal Investigator:     Nora E Straznicky, BPharm, PhD, MPH     Baker Heart Research Institute    
  More Information


Study ID Numbers:   7/05
First Received:   September 12, 2005
Last Updated:   July 31, 2007
ClinicalTrials.gov Identifier:   NCT00163943
Health Authority:   Australia: National Health and Medical Research Council

Keywords provided by Bayside Health:
Metabolic syndrome  
Sympathetic nervous system activity  
Insulin sensitivity  
weight loss  
aerobic exercise  

Study placed in the following topic categories:
Body Weight
Hyperinsulinism
Metabolic Diseases
Metabolic Syndrome X
Weight Loss
Syndrome X
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Insulin
Abdominal obesity metabolic syndrome

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers